Phase II trial

Sickle cells
#Beam Therapeutics #Cell therapy #Phase II trial #Sickle cell disorder (SCD)

Trial results support US biologics license application for risto-cel

Beam Therapeutics has shared positive topline results from the BEACON Phase I/II study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).   Risto-cel is an investigational one-time, autologous cell therapy with a potentially differentiated profile for the treatment of SCD. Read More

#News #Trending News

Cancer cells
#Combination therapy #Faeth Therapeutics #Oncology #Phase II trial

Preliminary data indicate durable responses for combo cancer therapy 

Faeth Therapeutics has announced topline clinical data from its Phase II trial of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel.  The drug is being trialled in patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR (PAM) pathway mutation, who had received at… Read More

#Cancer Research #Editor's Choice #News

Stamp of approval
#Phase II trial #Processa Pharmaceuticals #US Food and Drug Administration (FDA)

FDA clears Phase II study of VT-7208 in chronic spontaneous urticaria

The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase II study of Processa Pharmaceuticals’ VT-7208 in chronic spontaneous urticaria (CSU).  Processa is advancing VT-7208, a next-generation, CNS-penetrant, once-daily oral BTK inhibitor, across three Phase II proof-of-concept programmes, including… Read More

#News #Regulatory

Cancer cell
#Breast cancer #ESMO #NEC Bio #Oncology #Phase II trial

NEC presents Phase I/II results for individualised oral neoantigen therapy

NEC Bio has presented results from the Phase I/II TNBC clinical trial of its orally administered individualised neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC).   The findings were presented in an e-poster at the ESMO Congress… Read More

#Cancer Research #News #Trending News

Microbiome
#Financing #Microbiotica #Phase II trial #Ulcerative colitis (UC)

Microbiotica raises £36 million to advance into Phase II

Biopharma company Microbiotica has closed £36 million in Series C financing to support the advancement of its treatment for ulcerative colitis. The financing was led by British Business Bank, with participation from Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners. All existing Series B investors… Read More

#Business & Investment #News

Gene therapy
#Base editing #Beam Therapeutics #ESGCT #Lipid based nanoparticle (LNP) #Phase II trial

Initial data from Phase I/II trial of base editing therapy at ESGCT

Beam Therapeutics will present initial data from the ongoing Phase I/II clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa) at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT).   BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation… Read More

#News

#Alentis Therapeutics #Collaboration #CSL #Phase II trial

CSL and Alentis announce global partnership

CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases.  Under the terms of the agreement, Alentis will receive a… Read More

#Business & Investment #News #Trending News

MRI of the brain showing glioblastoma
#Brain cancer #Cancer vaccine #MimiVax #Oncology #Phase II trial

Cancer vaccine extends survival in glioblastoma trial

MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the SURVIVE Phase IIb clinical trial evaluating novel cancer vaccine, SurVaxM, in patients with newly diagnosed glioblastoma.  The data reflect the first reportable results from the fully enrolled clinical trial, which has been underway since 2022… Read More

#Cancer Research #News

Monoclonal antibodies
#Chronic obstructive pulmonary disease (COPD) #Connect Biopharma #Monoclonal antibodies #Phase II trial

Monoclonal antibody reduces COPD exacerbations in Phase II trial

Connect Biopharma has announced topline results from its global Phase II study evaluating rademikibart, a potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody.  The treatment was assessed as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. … Read More

#News

RNA strand
#Arrowhead Pharmaceuticals #Cardiovascular disease #Phase II trial #RNA therapy

Arrowhead’s RNA therapy silences two genes simultaneously

Arrowhead Pharmaceuticals has announced interim topline data from a Phase I/IIa clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia.   ARO-DIMER-PA is designed to silence expression of both… Read More

#News

#ENA Respiratory #Immunology / Virology & Vaccines #Phase II trial #Respiratory

Community study tests respiratory protective nasal spray

ENA Respiratory has dosed the first participants in Part B of its Phase IIa community study of INNA-051, a virus-agnostic, dry powder nasal spray.  INNA-051 is designed to prime the natural antiviral host defences in the nose where common respiratory viruses like rhinovirus, flu, RSV and coronaviruses… Read More

#News

#CONNECTA Therapeutics #Funding #Phase II trial #Rare disease

€3.1 million to support Fragile X syndrome programme

CONNECTA Therapeutics has closed a €3.1 million financing led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth, FCR fund.  The funds will support CONNECTA in accelerating the Phase IIa clinical trial of CTH120 in adult males with Fragile X syndrome (FXS). … Read More

#Business & Investment #News

#Infex Therapeutics #Monoclonal antibodies #Phase II trial #Respiratory

New Phase IIa data for RESP-X revealed at ERS Congress 2026

Infex Therapeutics has presented new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa).  The results were presented at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain. … Read More

#News

Intestinal tract
#Coeliac disease #Monoclonal antibodies #Phase II trial #Teva

Positive results for anti-IL-15 monoclonal antibody in coeliac disease

Teva Pharmaceutical has announced positive topline results from an ongoing Phase IIa study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with coeliac disease.   The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week… Read More

#News

Head and neck cancer
#Head and neck cancer #Oncology #Phase II trial #QBiotics

Phase II data show durable responses in head and neck cancer

QBiotics has announced positive results from its Phase II QB46C-H08 trial, with tigilanol tiglate achieving a 78% Objective Response Rate (ORR) in patients with head and neck solid malignancies who were refractory to standard of care.   The company says the result, based on 14 responses across 18… Read More

#Cancer Research #News

#Financing #Kynexis #Neuroscience #Phase II trial #Schizophrenia

Kynexis extends Series A to €97m to advance cognitive disorder drug

Kynexis has closed a €40 million Series A extension bringing the company’s total Series A financing to €97 million ($110 million).   The financing was led by new investor Novartis Venture Fund, with participation from existing investors Forbion, Ysios Capital, and Sunstone Life Science Ventures.   In… Read More

#Business & Investment #News